期刊文献+

3~4期慢性肾脏病合并高血压265例用药控制情况及影响因素分析 被引量:4

Blood control,current therapeutics and influencing factors in patients with stage 3 and 4 chronic kidney disease complicating with hypertension
暂未订购
导出
摘要 目的了解慢性肾脏病(CKD)3~4期合并高血压患者血压控制情况、治疗现状,分析其影响因素。方法分析2010年4月至2011年4月265例在北京友谊医院CKD门诊规律随访3个月以上的CKD 3~4期合并高血压的患者的临床资料和治疗情况。结果高血压知晓率为97.7%,知道正确靶目标值的患者占83%,血压控制在130/80 mmHg以下的CKD高血压患者占39.2%。服用3种以上降压药物的患者占19.6%,利尿剂使用比例6.8%。结论应加强对CKD合并高血压患者的教育及自我管理的培训,临床医师应给予患者更加积极合理的降压治疗,提高血压控制率,改善预后。 Objective To determine the blood control, current therapeutics and influencing factors in patients who had stage 3 and 4 chronic kidney disease (CKD) patients complicating with hypertension. Methods We analyzed the clinical and therapeutic profiles of 265 patients with stage 3 and 4 CKD complicating with hypertension who were followed-up regularly for at least 3 months from the CKD out-patient clinics, Peking Friendship Hospital. Results 97.7% of participants were a- ware of hypertension and 83% knew the correct target threshold. Blood pressure was maintained below 130/80 mmHg in 39.2% of patients who had stage 3 and 4 CKD complicating with hypertension. Triple medication regimen was prescribed in 19. 6% of patients, and 6. 8% were on diuretics therapy. Conclusion Education and self-management training in CKD pa- tients complicating with hypertension should be reinforced, and clinicians should be responsible for rational and active anti- hypertensive therapy, thereby improving blood control rate and prognosis.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2012年第3期205-208,共4页 Chinese Journal of Practical Internal Medicine
基金 北京市科学技术委员会资助课题(D09050704310903)
关键词 慢性肾脏病 高血压 血压控制 chronic kidney disease hypertension blood pressure control
  • 相关文献

参考文献11

  • 1Muntner P, He J,Astor BC, et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease : resuhs from the atherosclerosis risk in communities study [ J ]. J Am Soc Nephrol,2005,16(2) :529 -538.
  • 2Fox CS,Larson MG,Leip EP,et al. Predictors of new - onset kidney disease in a community - based population [ J ]. JAMA, 2004,291 (7) :844 -850.
  • 3Ruggenenti P, Perna A, Gherardi G, et al. Renal function and requirement for dialysis in chronic nephropathy patients on long - term ramipril : REIN follow - up trial [ J ]. Lancet, 1998,352 ( 9136 ) : 1252 - 1256.
  • 4Brenner BM,Cooper ME, de Zeeuw D,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and ncphropathy[ J]. N Engl J Med,2001,345 (12) :861 - 869.
  • 5Muntner P, Anderson A, Charleston J, et al. Hypertension Awareness,Treatment,and Control in Adults With CKD:resuhs from the Chronic Renal Insufficiency Cohort (CRIC) Study [ J ]. Am J Kidney Dis,2010,55(3) :441 -451.
  • 6Parikh NI, Hwang SJ, Larson MG, et al. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control [ J ]. Arch Intern Mcd, 2006, 166 ( 17 ) : 1884 - 1891.
  • 7Sarafidis PA, Li S, Chen SC, et al. Hypertension awareness, trealmeat, and control in chronic kidney disease [ J ]. Am J Med, 2008, 121 (4) :332 - 340.
  • 8Parikh NI, Hwang SJ, Larson MG, et al. Cardiovascular disease risk factors in chronic kidney disease:overall burden and rates of treatment and control [ J ]. Arch Intern Med, 2006, 166 ( 17 ) : 1884 - 1891.
  • 9张婧,张爱华,陈邵燕,程李涛,何莲,范敏华,汪涛.慢性肾脏病患者合并高血压情况及相关因素分析[J].中华高血压杂志,2010,18(9):855-860. 被引量:19
  • 10Wang Y, Zhang L, Li X, et al. Improvement of awareness, treatment and control of hypertension among chronic kidney disease patients in China from 1999 to 2005 [ J ]. Hypertens Res, 2009,32 (6) : 444 - 449.

二级参考文献25

  • 1张瑞岩,沈卫峰.慢性肾病与心血管疾病[J].中国循环杂志,2004,19(3):234-235. 被引量:7
  • 2Covic A, Goldsmith D. Ambulatory blood pressure monitoring: an essential tool for blood pressure assessment in uremic patients [J]. Nephrol Dial Transplant,2002,17(10):1737-1741.
  • 3Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988- 1994)[J]. Arch Intern Med, 2001,161 (9) : 1207-1216.
  • 4K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney disease outcome quality initiative 2002[J]. Am J Kid Dis,2002,39(suppl 2) : 7-10.
  • 5Lunde P, Baksaas I, Halse M, etal. The methodology of drug utilization studies. In: studies in drug utilization: WHO regional office for Europe-bergman U, Grimsson A, Wahba A, Werterholm B, eds. Copenhague. WHO Regional Office for Europe, 1997:17-28.
  • 6Maarten WT. Slowing the progression of adult chronic kidney disease[J]. Drugs, 2004,4 (20): 2273-2289.
  • 7Anil KB, Karen AG. Pathophysiology of hypertensive renal damage: implications for therapy[J]. Hypertension,2004,44(5):595- 601.
  • 8Muntner P, Anderson A, Charleston J, etal. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study[J]. Am J Kidney Dis,2010,55(3):441-451.
  • 9Wang Y, Zhang L, Li X, et al. Improvement of awareness, treatment and control of hypertension among chronic kidney disease patients in China from 1999 to 2005[J]. Hypertens Res, 2009,32(6) :444-449.
  • 10Cheng LT, Gao YL, Gu Y, etal. Stepwise increase in the prevalence of isolated systolic hypertension with the stages of chronic kidney disease[J]. Nephrol Dial Transplant, 2008,23 (12) : 3895- 3900.

共引文献34

同被引文献25

  • 1Muntner P, He J, Astor BC, et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study[ J]. J Am Soc Neph- rol,2005,16(2) : 529 -538.
  • 2Fox CS, Larson MG, Leip EP, et al. Predictors of new - onset kidney disease in a community - based population[ J]. JAMA, 2004,291 (7) : 844 - 850.
  • 3DG Hackam, NA Khan, BR Hemmelgarn, et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 - therapy[ J]. Can J Cardio1,2010,26 (5) :249 - 258.
  • 4Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on re- nal and cardiovascular outcomes in patients with type 2 diabetes and ne- phrepathy[J]. N Engl J Med,2001,345(12) :861 -869.
  • 5Muntner P, Anderson A, Charleston J, et al. Hypertension Awareness, Treatment, and Control in Adults With CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study [ J ]. Am J Kidney Dis, 2010,55(3) :441 -451.
  • 6Parikh NI, Hwang SJ, Larson MG, et al. Cardiovascular disease risk factors in chrenie kidney disease: overall burden and rates of treatment and control[ J]. Arch Intern Med,2006,166(17) :1884 -1891.
  • 7Sarafidis PA, Li S, Chen SC, et al. Hypertension awareness, treat- ment, and control in chrenie kidney disease [ J ]. Am J Med,2008,121 (4) :332 -340.
  • 8Cueto - Manzano AM, Marttnez - Ramfrez HR, Cortes - Sanabria L. Management of chronic kidney disease: primary health - care setting, self- care and multidisciplinary approach [ J ]. Clinical nephmlogy. 2010,74 ( Suppl. 1 ) : S99 - S104.
  • 9Kauric - Klein Z. Improving blood pressure control in end stage renal disease through a supportive education nursing intervention [ J]. Neph- rol Nuts J,2012,39(3) :217 -228.
  • 10Earl GL, Henstenburg JA. Dietary approaches to hypertension : a call to pharmacists to promote lifestyle changes [ J ]. J Am Pharm Assoc ,2012, 52(5) :637 -645.

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部